Yin Zhiying, Wen Tingcui, Fu Canya, Li Junji, Fang Quanjun, Gong Xiaoying, You Jialing, Wang Shuangqing, Zheng Canjie
Department of Immunoprevention, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China.
School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Front Immunol. 2024 Apr 10;15:1308238. doi: 10.3389/fimmu.2024.1308238. eCollection 2024.
Limited data were available on the effectivenessfour years after Homo or Hetero prime-boost with 10 μg Hansenulapolymorpha recombinant hepatitis B vaccine (HepB-HP) and 20 μgChinese hamster ovary cell HepB (HepB-CHO).
A crosssectional study was performed in maternalhepatitis B surface antigen (HBsAg)-negative children whoreceived one dose of 10 μg HepB-HP at birth, Homo or Heteroprime-boost with 10 μg HepB-HP and 20 μg HepB-CHO at 1 and 6months. HBsAg and hepatitis B surface antibody (anti-HBs) fouryears after immunization were quantitatively detected by achemiluminescent microparticle immunoassay (CMIA).
A total of 359 children were included; 119 childrenreceived two doses of 10 μg HepB-HP and 120 children receivedtwo doses of 20 μg HepB-CHO, called Homo prime-boost; 120children received Hetero prime-boost with 10 μg HepB-HP and 20μg HepB-CHO. All children were HBsAg negative. The geometricmean concentration (GMC) and overall seropositivity rate (SPR) ofanti-HBs were 59.47 (95%CI: 49.00 - 72.16) mIU/ml and 85.51%(307/359). Nearly 15% of the study subjects had an anti-HBsconcentration < 10 mIU/ml and 5.01% had an anti-HBsconcentration ≤ 2.5 mIU/ml. The GMC of the 20 μg CHO Homoprime-boost group [76.05 (95%CI: 54.97 - 105.19) mIU/ml] washigher than that of the 10 μg HP Homo group [45.86 (95%CI:31.94 - 65.84) mIU/ml] ( = 0.035). The GMCs of the Heteroprime-boost groups (10 μg HP-20 μg CHO and 20 μg CHO-10 μgHP) were 75.86 (95% CI: 48.98 - 107.15) mIU/ml and 43.65(95%CI: 27.54 - 69.18) mIU/ml, respectively ( = 0.041). Aftercontrolling for sex influence, the SPR of the 20 μg CHO Homoprime-boost group was 2.087 times than that of the 10 μg HPHomo group.
The HepB booster was not necessary in the generalchildren, Homo/Hetero prime-boost with 20 μg HepB-CHO wouldincrease the anti-HBs concentration four years after immunization,timely testing and improved knowledge about the self-pay vaccinewould be good for controlling hepatitis B.
关于使用10μg汉逊酵母重组乙型肝炎疫苗(HepB-HP)和20μg中国仓鼠卵巢细胞乙型肝炎疫苗(HepB-CHO)进行同源或异源初免-加强免疫四年后的有效性数据有限。
对母亲乙型肝炎表面抗原(HBsAg)阴性的儿童进行了一项横断面研究,这些儿童在出生时接种一剂10μg HepB-HP,并在1个月和6个月时进行同源或异源初免-加强免疫,分别接种10μg HepB-HP和20μg HepB-CHO。免疫四年后,通过化学发光微粒子免疫分析(CMIA)定量检测HBsAg和乙型肝炎表面抗体(抗-HBs)。
共纳入359名儿童;119名儿童接种两剂10μg HepB-HP,120名儿童接种两剂20μg HepB-CHO,即同源初免-加强免疫;120名儿童接受10μg HepB-HP和20μg HepB-CHO的异源初免-加强免疫。所有儿童HBsAg均为阴性。抗-HBs的几何平均浓度(GMC)和总体血清阳性率(SPR)分别为59.47(95%CI:49.00 - 72.16)mIU/ml和85.51%(307/359)。近15%的研究对象抗-HBs浓度<10 mIU/ml,5.01%的研究对象抗-HBs浓度≤2.5 mIU/ml。20μg CHO同源初免-加强免疫组的GMC[76.05(95%CI:54.97 - 105.19)mIU/ml]高于10μg HP同源组[45.86(95%CI:31.94 - 65.84)mIU/ml](P = 0.035)。异源初免-加强免疫组(10μg HP-20μg CHO和20μg CHO-10μg HP)的GMC分别为75.86(95%CI:48.98 - 107.15)mIU/ml和43.65(95%CI:27.54 - 69.18)mIU/ml(P = 0.041)。在控制性别影响后,20μg CHO同源初免-加强免疫组的SPR是10μg HP同源组的2.087倍。
一般儿童无需进行乙型肝炎疫苗加强免疫,使用20μg HepB-CHO进行同源/异源初免-加强免疫可提高免疫四年后的抗-HBs浓度,及时检测和提高对自费疫苗的认识有助于控制乙型肝炎。